1.上海中医药大学附属龙华医院,上海市宛平南路725号,200032
2.上海中医药大学护理学院
ET1978@163.com,(021)64385700转4308
收稿:2022-04-04,
修回:2022-10-01,
纸质出版:2023-01-02
移动端阅览
刘影,张春蕾,单亚维等.补肾健脾方含药血清对乙型肝炎病毒感染后树突状细胞亚群的影响[J].中医杂志,2023,64(01):55-61.
LIU Ying,ZHANG Chunlei,SHAN Yawei,et al.Effect of Bushen Jianpi Formula (补肾健脾方) Drug Containing Serum on Dendritic Cell Subsets after Hepatitis B Virus Infection[J].Journal of Traditional Chinese Medicine,2023,64(01):55-61.
刘影,张春蕾,单亚维等.补肾健脾方含药血清对乙型肝炎病毒感染后树突状细胞亚群的影响[J].中医杂志,2023,64(01):55-61. DOI: 10.13288/j.11-2166/r.2023.01.011.
LIU Ying,ZHANG Chunlei,SHAN Yawei,et al.Effect of Bushen Jianpi Formula (补肾健脾方) Drug Containing Serum on Dendritic Cell Subsets after Hepatitis B Virus Infection[J].Journal of Traditional Chinese Medicine,2023,64(01):55-61. DOI: 10.13288/j.11-2166/r.2023.01.011.
目的
2
探讨补肾健脾方对不同载量乙型肝炎病毒(HBV)感染后树突状细胞(DC)亚群抑制状态的影响。
方法
2
分离健康人外周血单个核细胞(PBMC),采用SD大鼠制备空白及补肾健脾方含药血清,采用HepG 2.2.15细胞株制备HBV病毒液。分为低病毒刺激(病毒浓度为1×10
5
IU/孔)和高病毒刺激(病毒浓度为1×10
7
IU/孔)实验。低病毒刺激实验每组设6个复孔,每孔细胞为1×10
6
,分为正常组一、低病毒组(病毒浓缩液1 μl)、空白血清组一(病毒浓缩液1 μl+10%空白血清200 μl)、补肾健脾方含药血清组一(病毒浓缩液1 μl+10%补肾健脾方含药血清200 μl);高病毒刺激实验每组设6个复孔,每孔细胞为1×10
6
,分为正常组二、高病毒组(病毒浓缩液100 μl)、空白血清组二(病毒浓缩液100 μl+10%空白血清200 μl)、补肾健脾方含药血清组二(病毒浓缩液100 μl+10%补肾健脾方含药血清200 μl)。两个实验均在干预12、24、36、48 h时采用流式细胞仪检测各组DC亚群髓样树突状细胞(mDC)和浆细胞样树突状细胞(pDC)含量。
结果
2
低病毒刺激实验中,补肾健脾方含药血清组一各时间mDC、pDC含量均高于同时间点空白血清组一、低病毒组(
P
<0.05);补肾健脾方含药血清组一mDC含量本组各时间点比较差异均无统计学意义(
P
>0.05),pDC含量12 h、24 h时较本组36 h、48 h低(
P
<0.05)。高病毒刺激实验中,补肾健脾方含药血清组二各时间mDC、pDC含量均高于同时间点空白血清组二和高病毒组(
P
<0.05);补肾健脾方含药血清组二pDC含量12 h、24 h时较本组36 h、48 h 低(
P
<0.05),mDC含量36 h时较12 h、24 h低,48 h时较12 h低(
P
<0.05)。不同载量HBV刺激12、24、36、48 h时,高病毒组及低病毒组mDC、pDC含量均随干预时间延长而降低(
P
<0.05);高病毒组各时间mDC含量均低于同时间点低病毒组(
P
<0.05),pDC含量仅12 h时低于低病毒组(
P
<0.05)。
结论
2
补肾健脾方含药血清可改善HBV对DC亚群的抑制,提高mDC、pDC含量进而增强机体对HBV的免疫应答。
Objective
2
To investigate the regulatory effect of Bushen Jianpi Formula (补肾健脾方, BJF) on the inhibition of dendritic cells (DC) subsets after infection with different hepatitis B virus (HBV)loads.
Methods
2
Peripheral blood mononuclear cells (PBMC) were obtained from healthy individuals. SD rats were used to prepare blank and BJP-containing serum, and HepG 2.2.15 cell line was used to prepare HBV virus liquid. The experiments were divided into low virus stimulation experiment (concentration of 1×10
5
IU/well) and high virus stimulation experiment (concentration of 1×10
7
IU/well). In the low virus stimulation experiments, 6 replicate wells each with 1×10
6
cells were set in the normal groupⅠ, low virus group (1 μl of concentrated virus fluid), blank serum groupⅠ (1 μl of concentrated virus fluid plus 200 μl of 10% blank serum), and BJF-containing serum groupⅠ (1 μl of concentrated virus fluid plus 200 μl of 10% BJF-containing serum). In the high virus stimulation experiments, 6 replicate wells each with 1×10
6
cells were set in the normal groupⅡ, high virus group (100 μl of concentrated virus fluid), blank serum groupⅡ (100 μl of concentrated virus fluid plus 200 μl of 10% blank serum), and BJF-containing serum groupⅡ (100 μl of concentrated virus fluid plus 200 μl of 10% BJF-containing serum). The content of myeloid dendritic cells (mDC) and plasmacytoid dendritic cells (pDC) of DC subsets in each group in the two experiments were detected by flow cytometry at 12 h, 24 h, 36 h and 48 h.
Results
2
In the low virus stimulation experiment, the contents of mDC and pDC in the BJF-containing groupⅠ were significantly higher than those in the blank serum groupⅠ and low virus stimulation group measured at the same timepoint (
P
<0.05), and were not significantly different in mDC content when compared between different timepoints in the BJF-containing groupⅠ (
P
>0.05); lower pDC measurements were found at 12 h and 24 h than at 36 h and 48 h in the other two groups (
P
<0.05). In the high virus stimulation experiment, the proportions of mDC and pDC in BJF-containing serum groupⅡ were higher than those in blank serum groupⅡ and high virus stimulation group measured at the same timepoint (
P
<0.05), and lower contents of pDC were found when measured at 12 h and 24 h than at 36 h and 48 h, and lower mDC contents at 36 h than at 12 h and 24 h, as well as at 48 h than at 12 h in the BJF-containing serum groupⅡ (
P
<0.05). The proportions of mDC and pDC in both high and low virus stimulation groups decreased with the increasing intervention time of HBV stimulation at different loadings at 12 h, 24 h, 36 h and 48 h (
P
<0.05). The proportion of mDC in the high virus stimulation group was lower than that in the low virus stimulation group at all timepoints (
P
<0.05), and pDC was lower than that in the low virus stimulation group only at 12 h (
P
<0.05).
Conclusion
2
BJF-containing serum can improve the inhibition of DC subsets by HBV and can increase the ratio of mDC and pDC, thus enhancing the body's immune response to HBV.
LIU J , LIANG W , JING W , et al . Countdown to 2030: eliminating hepatitis B disease, China [J]. Bull World Health Organ , 2019 , 97 ( 3 ): 230 - 238 .
SHI Y , ZHENG M . Hepatitis B virus persistence and reactivation [J]. BMJ , 2020 , 370 : m2200 . doi: 10.1136/bmj.m2200 http://dx.doi.org/10.1136/bmj.m2200 .
ZHANG Z , ZHANG JY , WANG LF , et al . Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection [J]. J Gastroenterol Hepatol , 2012 , 27 ( 2 ): 223 - 230 .
陈腾飞 , 刘清泉 . 浅述中医“正气”理论 [J]. 环球中医药 , 2016 , 9 ( 11 ): 1332 - 1335 .
王玉红 , 刘先勇 . 扶正祛邪思想在慢性乙型病毒性肝炎治疗中的应用 [J]. 内蒙古中医药 , 2019 , 38 ( 10 ): 155 - 157 .
DANDRI M , LOCARNINI S . New insight in the pathobio-logy of hepatitis B virus infection [J]. Gut , 2012 , 61 ( Suppl 1 ): 16 - 17 .
彭建平 , 陈晨 , 何芳 , 等 . 补肾法与健脾法对乙肝病毒感染免疫耐受期患者外周血树突状细胞功能的影响 [J]. 中西医结合肝病杂志 , 2010 , 20 ( 4 ): 221 - 224 .
王磊 , 杨丽丽 , 冯晓霞 , 等 . 健脾为主辨证治疗对慢性乙型肝炎患者外周血树突状细胞表型功能的影响 [J]. 中西医结合肝病杂志 , 2012 , 22 ( 1 ): 25 - 29,68 .
高月求 , 郑亚江 , 王灵台 . 健脾方对脾虚型慢性乙型肝炎患者树突细胞功能的影响 [J]. 中国中西医结合杂志 , 2007 , 27 ( 4 ): 300 - 302 .
李仪奎 . 中药药理实验方法学 [M]. 上海 : 上海科学技术出版社 , 2006 : 38 .
中华中医药学会肝胆病专业委员会 , 中国民族医药学会肝病专业委员会 . 慢性乙型肝炎中医诊疗指南 [J]. 临床肝胆病杂志 , 2018 , 32 ( 12 ): 2520 - 2525 .
XIA Y , GUO H . Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential [J]. Antiviral Res , 2020 , 180 : 104824 . doi: 10.1016/j.antiviral. 2020. 104824 http://dx.doi.org/10.1016/j.antiviral.2020.104824 .
CAO W . Molecular Characterization of human plasmacytoid dendritic cells [J]. J Clin Immunol , 2009 , 29 ( 3 ): 257 - 264 .
TANG F , DU QM , LIU YJ . Plasmacytoid dendritic cells in antiviral immunity and autoimmunity [J]. Sci China Life Sci , 2010 , 53 ( 2 ): 172 - 182 .
JU XS , CLARK G , HART DN , et al . Review of human DC subtypes [J]. Methods Mol Biol , 2010 , 595 : 3 - 20 . doi: 10.1007/978-1-60761-421-01 http://dx.doi.org/10.1007/978-1-60761-421-01 .
REIZIS B . Plasmacytoid dendritic cells: development, regulation, and function [J]. Immunity , 2019 , 50 ( 1 ): 37 - 50 .
DEN BROUW MLOP , BINDA RS , VAN ROOSMALEN MH , et al . Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus [J]. Immunology , 2009 , 126 ( 2 ): 280 - 289 .
ARIMA S , AKBAR SM , MICHITAKA K , et a1 . Impaired function of antigen-presenting dendritic cells inpatients with chronic hepatitis B: localization of HBV DNA and HBV RNA in blood DC by in situhybridization [J]. Int J Mol Med , 2003 , 11 ( 2 ): 169 - 174 .
VAN DER MOLEN RG , SPRENGERS D , BINDA RS , et al . Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B [J]. Hepatology , 2004 , 40 ( 3 ): 738 - 746 .
WOLTMAN AM , DEN BROUW MLOP , BIESTA PJ , et al . Hepatitis B virus lacks immune activating capacity,but actively inhibits plasmacytoid dendritic cell function [J]. PLoS One , 2011 , 6 ( 1 ): e15324 . doi: 10.1371/journal.pone.0015324 http://dx.doi.org/10.1371/journal.pone.0015324 .
ZHENG BJ , ZHOU J , QU D , et al . Selective functional deficitin dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection [J]. J Viral Hepat , 2004 , 11 ( 3 ): 217 - 224 .
LUO J , LI J , CHEN RL , et al . Autologus dendritic cell vaccine for chronic hepatitis B carriers: A pilot, open label, clinical trial in human volunteers [J]. Vaccine , 2010 , 28 ( 13 ): 2497 - 2504 .
BOONSTRA A , WOLTMAN AM , JANSSEN HL . Immunology of hepatitis B and hepatitis C virus infections [J]. Best Pract Res Clin Gastroenterol , 2008 , 22 ( 6 ): 1049 - 1061 .
0
浏览量
1
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号